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ABSTRACT 24 
Poor response to tuberculosis (TB) therapy might be attributable to sub-therapeutic levels in 25 
drug-compliant patients. Pharmacokinetic parameters can be affected by co-morbidities or the 26 
interaction of drugs with food.     27 
This study aimed to determine the effect of food intake upon pharmacokinetics of rifampicin 28 
and isoniazid in a Peruvian TB population. Rifampicin and isoniazid levels were analysed at 2, 4 29 
and 6 hours after drug intake in both fasting and non-fasting state using liquid chromatography 30 
mass spectrometric methods.  31 
Sixty patients participated in the study. The median rifampicin Cmax and AUC0-6 were higher 32 
on fasting days than non-fasting days: 7.02mg/L vs. 6.59mg/L (p:0.054) and 28.64mg·h/l vs. 33 
24.31mg·h/l (p:0.002). There was a statistically significant delay overall of non-fasting Tmax 34 
compared to the fasting state Tmax(p=0.005). In the multivariate analysis, besides the effect of 35 
fasting, Cmax for females was 20% higher than for males (p=0.03). Concerning isoniazid, there 36 
were significant differences in the Cmax on non-fasting day (median 3.51mg/L) compared with 37 
the fasting day (4.54mg/L). The isoniazid-dose received had an effect upon the isoniazid-levels 38 
(1.26,p:0.038). In the multivariate analysis, isoniazid-exposure on the fasting day was found to 39 
be 14% higher than on the non-fasting day (CI:1.02–1.28,p<0.001). Neither radiological extent 40 
of the disease nor consumption of food with drug intake nor pharmacokinetics of rifampicin or 41 
isoniazid was associated with a poorer treatment outcome. 42 
 Rifampicin in particular and also isoniazid pharmacokinetics were significantly affected by the 43 







The current first-line strategy to treat tuberculosis(TB) is based on the standardized short 50 
course regimen recommended by WHO of rifampicin(RIF), isoniazid(INH), pyrazinamide(PZA) 51 
and ethambutol(ETA) which is usually highly effective1. Despite the success of directly 52 
observed therapy(DOT) strategies1,2 in many TB endemic countries, relapse and acquired drug 53 
resistance has not been entirely eliminated3. Factors such as high baseline bacillary burden or 54 
sputum smear-positivity, cavitation, HIV, DM and other underlying diseases have been 55 
associated with poorer TB outcome4-7 and also with impaired pharmacokinetics8-11 . 56 
Recently, experimental and clinical studies have shown that pharmacokinetic variability 57 
expressed in key parameters such as plasma area-under-the-curve(AUC) seems to play an 58 
important role in the emergence of acquired multidrug-resistant TB(MDR-TB) in in vitro 59 
models; inadequate exposure to anti-TB drugs is associated with acquired drug resistance12,13. 60 
In prospective clinical studies, impaired pharmacokinetic studies have been related to a 61 
suboptimal treatment response14,15 though this is not a universal finding16-18 and 62 
concentrations below the expected range for key drugs in the anti-TB regimen have been 63 
frequently found in patients responding well to treatment19,20.  64 
Several studies suggest that bioavailability of RIF and INH is reduced by dosing the TB drugs 65 
with meals21-23, prompting recommendations that the drugs should be taken on an empty 66 
stomach. However, other studies showed no significant difference in the time for which the 67 
serum-rifampicin remained above the minimum inhibitory concentration(MIC) for  68 
Mycobacterium tuberculosis, suggesting that the chemotherapeutic effect is likely to be 69 
unaffected24. 70 
As anti-tuberculosis drugs can cause gastrointestinal upset which may impair adherence to 71 
therapy25-27, an adverse effect heightened by taking medication without food, the current 72 
official recommendation of the American Thoracic Society, is to provide TB medication with 73 
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meals if gastrointestinal intolerance persists28. However, few studies have evaluated if patients 74 
dosing the TB drugs with meals are associated with treatment failure or early relapse.  75 
OBJECTIVES 76 
The aim of this study was to determine the frequency and magnitude of any within-person 77 
difference in the pharmacokinetics of R and H in a group of patients taking TB treatment on an 78 
empty stomach or with food, and to determine the effect upon sputum smear and culture 79 
conversion times and end-of-treatment(EOT) and EOT+6 month disease outcomes of taking TB 80 
treatment predominantly with food or predominantly fasted during the course of treatment.  81 
 METHODS 82 
This observational study was conducted in Lima(Peru), from January-December,2012. People 83 
diagnosed with Pulmonary TB commencing supervised treatment under the DOTS programme 84 
of the Peruvian National TB programme(PNTP) were invited to participate. 85 
 The recommended scheduled by PNTP is a six days/week during the intensive 86 
phase(RIF,INH,PZA and ETA) and twice/week(RIF/INH) during the maintenance phase at the 87 
time of the study. RIF-dose is 10mg/Kg/day and INH-dose is 5mg/kg/day during the intensive 88 
phase of treatment.   89 
Patients who were not sputum smear positive, who were known to have co-morbid HIV 90 
disease or DM, or were unwilling or unable to give informed consent were excluded from the 91 
study. 92 
A semi-structured questionnaire was given to all participants. Personal data, information about 93 
their TB disease, gender, age, height(cm) and weight(Kg) were recorded and the body mass 94 
index(BMI) was calculated.  A chest radiograph was performed for all participants and the 95 
scored developed by Ralph et al29 was used to calculate the severity of pulmonary TB in each 96 
case.   97 
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All patients were given a diet diary (collected at weekly intervals) where they daily annotated, 98 
whether they had eaten and the kind of food in the period beginning 2-hours before, during or 99 
within 1-hour after the drug intake.    100 
At day 30 and 60, blood samples were drawn from each patient at the health-centre by 101 
dedicated staff into 10ml lithium-heparin tubes at 3 time points -two, four, and six hours after 102 
the directly-observed TB drug intake. On one of these days, patients were required to fast at 103 
least one hour before and an hour after the drug intake. 104 
Treatment outcome of patients was determined at end of therapy (by personal examination, 105 
chest radiography and conventional culture) and 6 months later either by a personal interview 106 
or a phone-call. 107 
Laboratory methods 108 
All blood samples were drawn and centrifuged in the health centres (centrifugation at 109 
2000rpm for 10min) and aliquots of the serum was refrigerated and transported to UPCH and 110 
stored at -70ºC until batched and transported to the pharmacokinetics laboratory of the 111 
Liverpool School of Tropical Medicine. RIF and INH concentrations in each blood sample were 112 
determined with validated assays9,10, described in detail in Annex 1.   113 
Pharmacokinetics outcome measurements 114 
For each patient, the Cmax was defined as the highest of the three concentrations measured 115 
at 2, 4 and 6 h, and the Tmax was the time point at which the Cmax occurred. PK parameters 116 
were obtained by non-compartmental analysis using the trapezoidal rule and the linear-up-117 
logdown method. MIC data were not available, and no additional analysis of PK-118 
pharmacodynamic(PD) parameters was developed. Although an internationally agreed-upon 119 
guideline for therapeutic drug monitoring is lacking, Cmax RIF values were also categorized as 120 
normal(>8mg/L), low(4-8mg/L) or very low(<4mg/L) in accordance with previous work21,30. 121 
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Normal INH-Cmax was defined, by comparison with existing pharmacokinetic data, as 3-122 
5mg/litre after a 5mg/kg daily21. INH-PK data were categorized according to Pasipanodya et al 123 
that established that a Cmax level of <2mg/litre after a 300-mg daily dose or a Cmax level of 124 
<7mg/litre after a 900-mg biweekly dose were regarded as inadequate31. 125 
Data analysis 126 
The chi-squared test was used for the comparison of proportions, and the Student t-test or 127 
Wilcoxon rank-sum test for paired samples was used for continuous variables, depending on 128 
variable distribution. The percentage of treatment days on which treatment was taken in a 129 
fasting state was derived for each individual from their diet diary, for use as a continuous 130 
exposure variable in the outcome analysis. The data were analysed with Stata-13.   131 
Ethics 132 
The study protocol and consent form were approved by the ethics committee of the London 133 
School of Hygiene and Tropical Medicine, Universidad Peruana Cayetano-Heredia and the 134 
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RESULTS 142 
Sixty patients were recruited to the study with a median age of 32.7(IQR 23.7-45 years); 143 
34(56.7%) were male. General characteristics of patients are summarized in table 1. The 144 
median RIF, INH, ETA and PZA dosages received were consistent with those recommended by 145 
the PNTP. 146 
Eight patients withdrew from the study before the first blood sample, two additional subjects 147 
were withdrawn after a subsequent new diagnosis of HIV and two more changed treatment 148 
regimen (one due to resistance and one due to adverse effects) so were also withdrawn. Thus 149 
48 patients had at least one PK data point and were included in the PK analysis(figure 1). 150 
Eleven patients could not be included in treatment outcome follow-up (six had changed 151 
therapy after PK sampling because of drug resistance and five abandoned either the therapy or 152 
the study). Thirty-seven participants were included in the follow-up evaluation. 153 
The information on the diet diaries was analysed for the 37 patients with follow-up treatment 154 
outcome data.  During the intensive phase, patients properly fasted (only drinking water) on a 155 
median of 2% of the treatment days (interquartile-range 1-7.5) and they took the TB drugs 156 
with water or any other drink (juice, cereal or carbonated beverages) without solid food a 157 
median of 4.5% of the treatment days(IQR:1-11.5).  The rest of the treatment days, patients 158 
consumed some food during drug intake. 159 
During the maintenance phase, patients fasted (only drinking water) with the drug intake a 160 
median of 1% of the treatment days(IQR:0-3) and they took the TB drugs either with water or 161 
with a drink without a meal a median of 4% of the treatment days(0-10). The rest of the 162 
treatment days, patients consumed some food during drug intake. 163 
PHARMACOKINETICS RESULTS 164 
Pharmacokinetics of rifampicin 165 
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Overall, median serum rifampicin levels at two, four and six hours were 3.25, 6.08 and 4.2mg/L 166 
respectively during the non-fasting day and 6.49, 6.08 and 4.23mg/L during the fasting day. 167 
The individual difference between RIF PK in the fasting day compared with the non-fasting day 168 
was particularly high at 2 hours (figure 2). 169 
Comparing PK parameters within individuals, the median Cmax and AUC0-6 were higher on 170 
fasting days than non-fasting days: 7.02mg/L vs. 6.59mg/L(p=0.054) and 28.64mg·h/l vs. 171 
24.31mg·h/l(p=0.002, Wilcoxon signed rank test) respectively.  172 
RIF-Cmax, when RIF was taken in a non-fasting state, was significantly lower in male compared 173 
with female patients (6 vs. 8.3mg/litre;p=0.035); however this effect of gender was not 174 
apparent when RIF was taken in a fasting state (6.73 versus 7.55mg/litre;p=0.09). 175 
Though not statistically significant there was also a tendency towards lower RIF AUC0-6 in male 176 
compared with female patients with dosing in both the fasting (27.85 vs. 31.75mg·h/l;p=0.09) 177 
and non-fasting state (22 vs. 27.27mg·h/l;p=0.08). 178 
Effect of fasting on Tmax 179 
On fasting days, Tmax occurred at 2, 4 or 6 hours in 68.8%, 27.1% and 4.2% of patients 180 
respectively. On non-fasting days, Tmax occurred at 2, 4 or 6 hours in 34.8%, 56.5%, and 8.7% 181 
respectively, a statistically significant delay overall compared to the fasting state 182 
Tmax(p=0.005,Wilcoxon Signed-rank test). Tmax was not associated with gender, age group, or 183 
dose received (data not shown). 184 
Categorization of Cmax: Adequate vs. inadequate levels. 185 
When non-fasting, three patients(6.5%) had Cmax values of <4mg/L, 28(60.9%) had rifampicin 186 
levels between 4-8mg/L, and 15(32.6%) had values that are regarded as adequate levels for 187 
TDM(>8mg/L). When the blood sampling was done during the fasting day, 1(2.1%) had a Cmax 188 
value of <4mg/L, 30(62.5%) had levels between 4-8mg/L, and 17 patients(35.4%) had normal 189 
levels (>8mg/L)(figure 3). Considering rifampicin AUC0-6 values <13mg.h/L as  low or inadequate 190 
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levels of AUC0-24, as suggested elsewhere14,  13% of patients had a low AUC during the fasting 191 
day compared with 2.1% during the non-fasting day. 192 
Multivariate analysis 193 
A model was constructed to assess the independent effect of fasting during drug intake, RIF-194 
Tmax and gender on the logarithm of RIF-Cmax.  RIF-Cmax on the fasting day was found to be 195 
15% higher than RIF-Cmax during the non-fasting day(CI:1.01–1.30,p<0.036). Cmax for females 196 
was 20% higher than for males(p=0.03). The effect of Tmax did not influence the Cmax (Tmax-197 
4h: 0.98,p=0.9; Tmax 6h: 1.11,p=0.676)(table 2). 198 
A further model was constructed to assess the independent effect of fasting during drug 199 
intake, the RIF-Tmax and gender on the logarithm of RIF-AUC0-6.   200 
RIF-AUC0-6 on the fasting day was found to be 14% higher than RIF-AUC0-6 during the non-201 
fasting day(CI:1.01–1.28, p<0.02).  RIF-AUC0-6 for females was 20% higher than for 202 
males(p:0.027). When RIF-Tmax occurred at 4h, RIF-AUC0-6 was reduced by 20% (p=0.002) and 203 
when it occurred at 6h, the RIF-AUC0-6 decreased by 50%(p<0.001), as compared with a RIF-204 
Tmax of 2 hours. 205 
Pharmacokinetics of INH 206 
Overall, median serum isoniazid levels at two, four and six hours were 3.27, 1.96 and 0.92mg/L 207 
respectively during the non-fasting day and 4.54, 1.19 and 0.75mg/L during the fasting day.  208 
The individual difference between INH-PK in the fasting day compared with the non-fasting 209 
day was particularly high at 2 hours(figure 4).  210 
There were significant differences in the Cmax on non-fasting day(median 3.51mg/L) 211 
compared with the fasting day(4.54mg/L)(Wilcoxon Signed-rank test p<0.001). The AUC0-6 was 212 
12.11mg·h/L on the non-fasting day vs. 13.31mg·h/L during the fasting day(p=0.001).  213 
 214 
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INH-Cmax in men was not different to INH-Cmax in women, whether fasted(4.21mg/L v. 215 
4.88mg/L;p=0.21) or not (3.29mg/L v 4.41mg/L respectively,p=0.08). Similarly, INH AUC0-6 did 216 
not differ between males and females either with fasting(13.21mg·h/L vs. 15.13mg·h/L,p=0.28) 217 
or non-fasting dosing conditions(12.08mg·h/L vs. 12.65mg·h/L,p=0.36). INH-Cmax was not 218 
affected by presence of intestinal parasites, age group or BMI (data not shown). 219 
Effect of fasting on INH-Tmax 220 
Tmax occurred at two hours in 80.4% and 95.8% of patients on the non-fasting and fasting day 221 
respectively, at 4 hours in 17.4% (non-fasting) and 2.1%(fasting), and at 6 hours in 2.2%(non-222 
fasting day) and 2.1%(fasting day) of patients; a statistically significant delay due to non-fasting 223 
(p=0.023,Wilcoxon Signed-rank test). 224 
Tmax was not associated with gender, age group, intestinal parasitic infection, or dose 225 
received (data not shown) regardless of fasting condition. 226 
On the non-fasting day, seven patients(15.2%) had Cmax values of <2mg/L, and 39(84.8%) had 227 
values that are regarded as adequate levels. When INH was taken in a fasting condition, 3 228 
(6.3%) had Cmax values of <2mg/L, 45(93.8%) had adequate levels(>2mg/L)(figure 5). 229 
However, considering isoniazid AUC0-6 values <52mg.h/L as  low or inadequate levels of AUC0-24, 230 
as suggested by Pasipanodya et al14,  100% of patients had a low  AUC during the fasting day 231 
compared with 95% during the non-fasting day(p=0.162),   232 
A model was constructed to assess the independent effect of gender, INH-dose received and 233 
the effect of fasting during drug intake on the logarithm of INH-Cmax(table 3). 234 
The INH-dose received had an effect upon the INH-levels(1.26,p:0.038). Moreover, INH-235 
exposure on the fasting day was found to be 14% higher than on the non-fasting day(CI:1.02–236 
1.28, p<0.001)(Table 3). A further model was constructed to assess the independent effect of 237 
gender, INH-Tmax and the effect of fasting during drug intake on the INH-AUC0-6.   238 
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INH-AUC0-6 was found to be 22% higher on the fasting than the non-fasting day(CI: 1.09–1.38, 239 
p<0.001. When INH-Tmax occurred at 6h, INH-AUC0-6 decreased by 47%(p=0.013).  240 
 All 37 patients evaluated at the end of therapy were considered cured. 1/37 patients 241 
evaluated at six months after the end of the therapy had relapsed two months after having 242 
finished the therapy. This 47 year-old male had successfully completed first line TB therapy 243 
with clinical and radiological improvement; although a fibrotic right apical scar was seen at end 244 
of therapy TB culture at this time was negative. Two months later he restarted TB therapy 245 
after an early microbiology confirmed relapse with a positive culture was diagnosed. The Rx-246 
score of this patient had been 42(median Ralph score 22.6). He had fasted 16% of the time 247 
during the intensive phase and had not fasted on any occasion in the maintenance phase. 248 
For the 37 subjects with treatment outcome data, neither the Rx score nor consumption of 249 
food with drug intake nor RIF-PK or INH-PK were associated with a poorer treatment outcome 250 
(data not shown). 251 
 252 
 253 
  254 
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DISCUSSION 255 
The results of this study demonstrate that RIF in particular and also INH pharmacokinetics 256 
(Cmax, Tmax and AUC0-6) were significantly affected by the intake of the drug with food, as has 257 
been shown previously32. However, the effect of food was not large and was highly variable 258 
between individuals, with some participants achieving higher exposure on non-fasted than 259 
fasted days.  260 
A delay in RIF absorption was observed and the median Tmax occurred at 4 hours instead of 2 261 
hours amongst those who took drug with food. By excluding inter-individual variability this 262 
intra-individual PK analysis demonstrated the interaction of the food during drug intake in the 263 
absorption delay (Tmax) and also in the AUC0-6, which has been corroborated in the 264 
multivariate analysis. As has been suggested before and further confirmed by our data here, 265 
slower absorption leads to lower plasma concentrations33.  266 
When RIF was ingested with food, low levels of RIF were observed in more than half of 267 
patients although very low levels (<4mg/L) were only observed in less than 10% of patients.  268 
Lower levels of RIF-Cmax and lower RIF-AUC0-6 were demonstrated among non-fasted men 269 
compared with women. Although this was not observed when the drug was taken on an empty 270 
stomach, in multivariate analysis gender influenced the pharmacokinetics of RIF regardless of 271 
fasting status. These gender differences give cause for consideration of whether dosing 272 
recommendations warrant review, though in the absence of a demonstrable impact upon 273 
treatment outcome, this is probably premature34. 274 
INH-Tmax occurred at 2-hours regardless of fasting status although the PK parameters (Cmax) 275 
were higher in the fasting blood sampling; other studies have suggested that food causes an 276 
absorption delay and also reduces the Cmax35.  277 
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It has been suggested that INH-Tmax may sometimes occurs earlier than 2 hours and we would 278 
not have captured this as our earliest sampling time point was 2 hours. The multivariate 279 
analysis also demonstrated the effect of fasting on increasing the exposure to INH.  280 
In both univariate and multivariate analysis INH-AUC0-6 and INH-Cmax did not differ by gender 281 
in either fasted or non-fasted state.   282 
The study was carried out under real-life field conditions and not in the controlled 283 
environment of a dedicated PK unit, what could influence the variability of RIF and INH PK.  284 
Conversely, this design generates more translatable data since patients are doing what they do 285 
every day.  Another strength of this study is that we were able to eliminate the confounding 286 
effect of inter-individual variability upon interpretation of the effect of food, because patients 287 
had blood sampling under both fasting and under non-fasting conditions, and a corresponding 288 
matched analysis was performed. 289 
It is usually recommended that RIF and INH are to be given on an empty stomach whenever 290 
possible, based on previous PK studies36. However, few studies have evaluated if patients 291 
dosing the TB drugs with meals are associated with treatment failure or early relapse.  In the 292 
US Public Health Service TB Trial-22 in which patients received rifapentine/isoniazid, patients 293 
receiving medication under fed conditions were significantly associated with treatment failure 294 
or relapse although patients were receiving INH and rifapentine instead of RIF12. However the 295 
exquisite dependence of rifapentine PK is well recognised so these data are not directly 296 
relevant.  297 
A secondary aim of our study was to determine if taking TB drugs with meals is associated with 298 
a poor response to treatment, an impact that could be hypothesized might result from lower 299 
drug exposure. In the event participant diet diaries demonstrated the real world reality in that 300 
most patients did not fast on most days around the time of drug intake in either the intensive 301 
or maintenance phase. As a result the exposure risk (taking TB drugs in an unfasted state) was 302 
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recorded for 98-99% of patients; furthermore there was only one recorded adverse outcome 303 
due to an early relapse, resulting in such low power as to render an analysis futile. A limitation 304 
of our study design is that follow-up for relapses was short at 6 months, so later relapses 305 
would not have been detected. We did not record side-effects and were thus unable to 306 
determine whether fasting increased the likelihood of them. 307 
It seems clear that lower serum concentrations, particularly with RIF can still be part of an 308 
effective therapy regimen in most patients. However, we could not accurately measure the 309 
effect of how the combination therapy might have positively influenced the treatment 310 
outcome. Although this synergistic effect can potentially be measured through a microdilution 311 
checkerboard assay37, drug susceptibility testing is done individually for each drug38. Thus, any 312 
effect of a low RIF or INH concentration might be overcome by the effect of the other agents 313 
and thus not directly influence treatment outcome.  The study was not designed to definitively 314 
prove whether poorer outcome was associated with RIF or INH-exposure. In this under-315 
powered sub-analysis, the treatment outcome was neither influenced by impaired 316 
pharmacokinetics (RIF or INH) or by difference in the intake of TB drugs with food. However, 317 
the small number of poor treatment outcomes means that this could represent a type-II error. 318 
But it could also be that the effect of food on plasma-PK is insufficiently large to impact upon 319 
response to treatment either because there are other factors which dominate or because the 320 
bit of redundancy in multi drug therapy compensates for this. Moreover, we had hoped to be 321 
able to tease out a gradient of different categories of how much patients took their drugs 322 
fasting (e.g.: “most”,“some”,“rarely”) and compare outcomes (“treatment outcomes” and 323 
“conversion times”) but almost all were “rarely” fasting so this was not possible. 324 
 325 
Although we have observed “subtherapeutic” Cmax levels of RIF in around 30% of patients, 326 
only one patient finally reported a bad treatment outcome. Interestingly when we calculate 327 
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low rifampicin exposure through AUC parameters, we observe that only 13% had low AUC 328 
exposure. Therefore, further investigation is needed to ascertain whether a review of the 329 
purported normal RIF-Cmax >8µg/mL is warranted and if the AUC-threshold proposed from 330 
hollow-fibre model studies14 is a suitable predictor of treatment outcome.  331 
Concerning INH, most patients had normal Cmax values. In contrast, if we consider the 332 
threshold of 52mgh/L suggested by Pasipanodya14, most patients would be classified as having 333 
had a low INH-exposure. A main limitation of considering the AUC as a marker of drug 334 
exposure is that we had to calculate the AUC0-6  instead of AUC0-24 as suggested elsewhere14 335 
due to the limited sample points in our study. 336 
It should be added that it is unclear what is the crucial determinant of drug efficacy at the 337 
cellular level and, if so, what the minimum drug exposure (in plasma) needs to be in order to 338 
have a high probability of efficacy. 339 
Although therapeutic drug monitoring(TDM) is neither widely used nor recommended during 340 
TB treatment, TDM might contribute not only to the identification patients with low levels of 341 
RIF or INH but also to a shrinking the time to response and also the duration of treatment39. A 342 
two and six hour post-dose sampling strategy may facilitate the analysis of both agents and it 343 
seems reasonable and practical.  344 
CONCLUSIONS 345 
 RIF in particular and also INH pharmacokinetics (both Cmax and AUC0-6) were significantly 346 
affected by the intake of the drug with food in a proportion of patients. A clear relationship 347 
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                                                                                                                                                                                                                                                                                     TB     n (%) 
Sex (Male) 34 (56.7) 
Age (years) 32.7 (23.7-45) 
BMI (Kg/m²)a 21.8 (19.8-24.4) 
Chronic diarrhoea 2 (3.33) 
Intestinal parasite 4 (7.7) 
Hospitalization  4 (6.67) 
HIV (n=56) 2 (3.57) 
TB type  
    New 
    Relapse />6 months) 
 
53 (88.3) 
 7 (11.67) 
Sputum smear        + 
                                ++ 





  Weight loss (n=59) 
  Cough 
  Fever (n=59) 
  Thoracic pain 
  Dyspnoea 
  Haemoptysis 
  Sweating 














44 positive (not undertaken in 16) 
41 pos, 7 neg 
RIF dosage (mg/Kg/day) 10.2 (9.6-11.2) 
INH dosage (mg/Kg/day) 5.1 (4.8-5.6) 
EMB dosage ((mg/Kg/day) 20.3 (19.1-22.4) 
PZA dosage (mg/Kg/day) 25.4 (23.9-28) 
Radiograph (Ralph score)*  22.6 (12.6-40.2) 
n= 60 unless specified; a. Numbers are expressed in median and 
Interquartile range. *Ralph score obtained in the Chest radiography 
evaluation =  % of affected lung + 40 (if cavitation is present) 
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Table 2.  Multilevel linear model of the independent association of variables with rifampicin 587 
exposure (Cmax) 588 
 589 
Variable Proportional difference CI p-value 
Fasting 1.15* 1.01-1.3 0.036 
Tmax 4h 0.98 0.77-1.26 0.901 
Tmax 6h 1.11 0.69-1.78 0.676 
Sex 1.2† 1.02- 1.41 0.027 
Note: The model was considered based on the natural logarithm of the Cmax values. The proportional 
difference was calculated as the exponential of the coefficient obtained for each variable in the 
multilevel linear model. Interpretation of the proportional difference: * Rifampicin Cmax on the fasting 
day was 15% higher than rifampicin Cmax during the non-fasting day.  † rifampicin Cmax in females 




  592 
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Table 3 . Multivariate regression model of the independent association of variables with 593 
isoniazid exposure (Cmax) 594 
 595 
Variable Proportional difference CI p-value 
Fasting 1.14* 1.02-1.28 <0.001 
Sex 1.26 1.08 – 1.48 0.176 
Isoniazid dose 1.25 1.01-1.53 0.038 
Note: The model was considered based on the natural logarithm of the Cmax values. The proportional 
difference was calculated as the exponential of the coefficient obtained for each variable in the 
multivariate model. Interpretation of the proportional difference: * Isoniazid Cmax on the fasting day 
was 14% higher than isoniazid Cmax during the non-fasting day.  † 
596 
 24 
Figure 1. TB diagram about patients recruitment and follow-up during the study. 597 
Figure 2. Difference in rifampicin concentration at three time-points according to fasting status 598 
(fasted minus unfasted). 599 
Figure 3 Frequency distribution of rifampicin Cmax categories during the non-fasting and the 600 
fasting day. 601 
Figure 4 .  Difference in isoniazid concentration at three time-points according to fasting status 602 
(fasted minus unfasted). 603 
Figure 5.  Frequency distribution of isoniazid Cmax categories during the non-fasting and the 604 
fasting day 605 
  606 
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Annex 1:  High-performance liquid chromatography (HPLC) assays. 607 
 608 
 609 
 610 
 611 
